Protocols

LogicBio guns for $75M IPO; Alexandria lands a new biotech building on Long Island

→ Prolific life-science developer Alexandria Real Estate Equities just plopped down $75M for a building in Long Island City fresh off the heels of its purchase of Pfizer HQ in Manhattan earlier this year.

→ Cambridge-based LogicBio is aiming for a $75 million haul during its IPO run. The gene editing company is looking to beef up its coffers for a Phase I/II run on methylmalonic acidemia (MMA). It will list under $LOGC on Nasdaq.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->